Literature DB >> 18845374

Evaluation of the accuracy of intra-operative gross examination for the surgical management of endometrial cancer.

Yuyan Mao1, Xiaoyun Wan, Yaxia Chen, Weiguo Lv, Xing Xie.   

Abstract

OBJECTIVE: The aim of this study was to explore the clinical value of intra-operative gross examination for the surgical management of endometrial carcinoma. STUDY
DESIGN: A retrospective study was conducted in 424 women who underwent surgical treatment for endometrial carcinoma between January 2002 and December 2006. The results of myometrial invasion and cervical infiltration as assessed by intra-operative gross examination were compared with the final microscopic histopathological results in 401 patients. The accuracy, sensitivity, and specificity were calculated. Chi-squared or Fisher's exact tests were used for the comparison of categorical variables.
RESULTS: Intra-operative gross examination correctly identified the depth of microscopic myometrial invasion in 90.3% of patients. The sensitivity in detecting myometrial invasion was 80.6% and the specificity was 92.4%. With regard to cervical involvement, gross examination had an overall accuracy of 84.3%. The sensitivity in detecting cervical involvement was 32.6% and the specificity was 99.0%. Usually, cervical involvement cannot be correctly identified by intra-operative gross examination in patients with diffuse foci.
CONCLUSION: The data suggest that intra-operative gross examination is a simple and good method of predicting myometrial invasion, but it may not be the ideal way to assess cervical involvement in endometrial carcinoma.

Entities:  

Mesh:

Year:  2008        PMID: 18845374     DOI: 10.1016/j.ejogrb.2008.07.033

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  1 in total

Review 1.  Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome.

Authors:  Robert A Soslow
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.